

Max J Schmulson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6434609/publications.pdf>

Version: 2024-02-01

91
papers

4,747
citations

172457

29
h-index

102487

66
g-index

102
all docs

102
docs citations

102
times ranked

3805
citing authors

#	ARTICLE	IF	CITATIONS
1	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e945-e956.	4.4	52
2	Bacterial and Fungal Gut Dysbiosis and <i>Clostridium difficile</i> in COVID-19. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 285-298.	2.2	16
3	Gastrointestinal symptoms and the severity of COVID-19: Disorders of gut-brain interaction are an outcome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14368.	3.0	26
4	Pictograms are more effective than verbal descriptors in Spanish for bloating and distension. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14364.	3.0	6
5	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	1.3	913
6	The human translation of the postinfectious irritable bowel syndrome like rat model with antivinculin production after immunization with cytolethal distending toxin B. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14042.	3.0	0
7	Probiotics: To Use or Not to Use? That Is the Question. <i>American Journal of Gastroenterology</i> , 2021, 116, 1396-1397.	0.4	1
8	The Impact of COVID-19 Pandemic on Neurogastroenterologists in Latin America. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 684-690.	2.2	7
9	Managing the Inevitable Surge of Post-COVID-19 Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2021, 116, 4-7.	0.4	51
10	Efficacy of the Combination of Pinaverium Bromide 100mg Plus Simethicone 300mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, e30-e39.	2.2	8
11	Mucosal Microbiome Profiles Polygenic Irritable Bowel Syndrome in Mestizo Individuals. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 72.	3.9	4
12	Alerta: los síntomas gastrointestinales podrán ser una manifestación de la COVID-19. <i>Revista De Gastroenterología De México</i> , 2020, 85, 282-287.	0.2	49
13	Ethnicity and other COVID-19 death risk factors in Mexico. <i>Archives of Medical Science</i> , 2020, 18, 711-718.	0.9	10
14	Trends of SARS-Cov-2 infection in 67 countries: Role of climate zone, temperature, humidity, and curve behavior of cumulative frequency on duplication time. <i>Medical Research Archives</i> , 2020, 8, .	0.2	2
15	Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case-control study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13693.	3.0	0
16	Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13718.	3.0	46
17	Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1033-1041.	3.8	50
18	Is Post Infection-Irritable Bowel Syndrome Less Frequent in Mexico?. <i>American Journal of Gastroenterology</i> , 2019, 114, 846-848.	0.4	1

#	ARTICLE	IF	CITATIONS
19	SÍntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicéntrica en México. Revista De Gastroenterología De México, 2019, 84, 44-51.	0.2	9
20	A low frequency of post infection-IBS in patients attended in a tertiary referral center in México. Revista Espanola De Enfermedades Digestivas, 2019, 111, 914-920.	0.3	0
21	Irritable Bowel Syndrome on the US Mexico Border. Journal of Clinical Gastroenterology, 2018, 52, 622-627.	2.2	3
22	Fecal microbiota transfer for bowel disorders: efficacy or hype?. Current Opinion in Pharmacology, 2018, 43, 72-80.	3.5	15
23	How to use Rome IV criteria in the evaluation of esophageal disorders. Current Opinion in Gastroenterology, 2018, 34, 258-265.	2.3	21
24	Mucosal Mast Cells Are Increased in the Small Intestine of Patients With Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2018, 113, S261-S262.	0.4	0
25	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut, 2017, 66, 1075-1082.	12.1	368
26	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology, 2017, 112, 775-784.	0.4	525
27	Respuesta a Carmona R.: ¿Están realmente listos los anticuerpos anti-CdtB y antivinculina para emplearse en pacientes con diarrea en México? A propósito de la colitis microscópica. Revista De Gastroenterología De México, 2017, 82, 197-199.	0.2	1
28	A Study of Microbial Diversity in Colonic Biopsies of Patients With Irritable Bowel Syndrome in Mexico Using High-Throughput Sequencing. American Journal of Gastroenterology, 2017, 112, S240-S241.	0.4	0
29	What Is New in Rome IV. Journal of Neurogastroenterology and Motility, 2017, 23, 151-163.	2.4	499
30	Maturation Phenotype of Peripheral Blood Monocyte/Macrophage After Stimulation with Lipopolysaccharides in Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2017, 23, 281-288.	2.4	6
31	World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2016, 50, 704-713.	2.2	90
32	450 Hydrogen- and Methane- Based Breath Testing (BT) in Gastrointestinal (GI) Disorders: Report of the North American Consensus Meeting. Gastroenterology, 2016, 150, S97.	1.3	4
33	Multicultural Aspects in Functional Gastrointestinal Disorders (FGIDs). Gastroenterology, 2016, 150, 1344-1354.e2.	1.3	54
34	Design of Treatment Trials for Functional Gastrointestinal Disorders. Gastroenterology, 2016, 150, 1469-1480.e1.	1.3	195
35	Experiencia clínica con el uso de los anticuerpos anti-CdtB y anti-vinculina en pacientes con diarrea en México. Revista De Gastroenterología De México, 2016, 81, 236-239.	0.2	12
36	Tu1795 Increased Number of Tryptase-Positive Mast Cells in the Colonic Mucosa of IBS Patients in Mexico and Its Relation With Perceived Stress. Gastroenterology, 2016, 150, S949-S950.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Tu1802 Colonic Immune Cells in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S951-S952.	1.3	0
38	From gene polymorphisms to serum cytokine levels in irritable bowel syndrome. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 525-527.	1.5	2
39	A Survey Using the Social Networks Revealed Poor Knowledge on Fecal Microbiota Transplantation. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 294-295.	2.4	2
40	Mo2042 TNF \pm in Irritable Bowel Syndrome (IBS): From Gene Polymorphisms to Circulating Levels. <i>Gastroenterology</i> , 2015, 148, S-777.	1.3	1
41	Mo1297 Mexican Patients Do Not Understand the Term Abdominal Distension. <i>Gastroenterology</i> , 2015, 148, S-665.	1.3	2
42	Incremento en las publicaciones cientÍficas sobre sÁndrome de intestino irritable en MÃ©xico y LatinoamÃ©rica. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2015, 80, 228-235.	0.2	2
43	Regulaci3n inmune anormal en niÃ±os con sÁndrome de intestino irritable. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2015, 80, 3-5.	0.2	2
44	¿Una dieta baja en FODMAP mejora los sÁntomas en pacientes mexicanos con SII?. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2015, 80, 177-179.	0.2	3
45	Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?. <i>Current Drug Targets</i> , 2015, 16, 199-208.	2.1	12
46	Microbiota, infecciones gastrointestinales, inflamaci3n de bajo grado y antibioticoterapia en el sÁndrome de intestino irritable. Una revisi3n basada en evidencias. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2014, 79, 96-134.	0.2	38
47	El aÃ±o 2014 en la Revista de GastroenterologÃa de MÃ©xico. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2014, 79, 217-219.	0.2	0
48	A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1368-1385.	3.0	41
49	Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. <i>Revista De GastroenterologÃa De MÃ©xico (English)</i> Tj ETQq1 1 0.284314zgBT /Ov		
50	Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response to pathogen-associated molecular patterns stimulation in patients with <scp>IBS</scp>. <i>Neurogastroenterology and Motility</i> , 2013, 25, 872.	3.0	18
51	IL-10 and TNF- α polymorphisms in subjects with irritable bowel syndrome in Mexico. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 392-399.	0.3	23
52	Irritable Bowel Syndrome and Gastrointestinal Parasite Infection in a Developing Nation Environment. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	1.5	19
53	The Epidemiology of Functional Gastrointestinal Disorders in Mexico: A Population-Based Study. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	1.5	75
54	Editorial: Abnormal Immune Regulation and Low-Grade Inflammation in IBS: Does One Size Fit All?. <i>American Journal of Gastroenterology</i> , 2012, 107, 273-275.	0.4	30

#	ARTICLE	IF	CITATIONS
55	A Global Perspective on Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 356-366.	2.2	124
56	Mo1017 Significant Differences in the ROME II and ROME III Determinations of Functional Gastrointestinal Disease Prevalence: Results From Population-Based Studies in Central America. <i>Gastroenterology</i> , 2012, 142, S-573.	1.3	3
57	Tu1426 The ROME III Adult Questionnaire in Spanish-Mexico Has a Low Sensitivity for Identifying IBS and Higher Sensitivity for Uninvestigated Dyspepsia. <i>Gastroenterology</i> , 2012, 142, S-829-S-830.	1.3	15
58	Lower Serum IL-10 Is an Independent Predictor of IBS Among Volunteers in Mexico. <i>American Journal of Gastroenterology</i> , 2012, 107, 747-753.	0.4	48
59	Can Pinaverium Bromide Plus Simethicone Improve Bloating and Objective Abdominal Distention During a 12-Week Randomized-Clinical Trial in IBS? A Report From the Mexican IBS-Working Group. <i>Gastroenterology</i> , 2011, 140, S-613.	1.3	1
60	Increased Intra Epithelial Lymphocytes and Decreased Mucosal Mast Cells in a Mexican Population Compared to the United Kingdom: Effects of Childhood Living Conditions. <i>Gastroenterology</i> , 2011, 140, S-533.	1.3	0
61	The Economic Burden of IBS in a Latin-American Population. A Report From the Mexican-IBS Working Group. <i>Gastroenterology</i> , 2011, 140, S-467.	1.3	0
62	Pinaverium Bromide Plus Simethicone is Effective on Abdominal Pain, in a 12-Week Randomized Placebo-Controlled Trial in IBS. A Report From the Mexican IBS-Working Group. <i>Gastroenterology</i> , 2011, 140, S-614.	1.3	0
63	From Cytokines to Toll-Like Receptors and Beyond - Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2010, 16, 363-373.	2.4	42
64	Differences in Gastrointestinal Symptoms According to Gender in Rome II Positive IBS and Dyspepsia in a Latin American Population. <i>American Journal of Gastroenterology</i> , 2010, 105, 925-932.	0.4	36
65	M1350 Multinational Validation of the Spanish ROME III Adult Diagnostic Questionnaire: Comparable Sensitivity and Specificity to English Instrument. <i>Gastroenterology</i> , 2010, 138, S-386.	1.3	6
66	Heartburn according to Rome II in Spanish-Mexico: gastroesophageal reflux must be ruled out. <i>Revista De Gastroenterología De México</i> , 2009, 74, 74-6.	0.2	3
67	How safe and effective is the herbal drug STW 5 for patients with functional dyspepsia?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 136-137.	1.7	4
68	Further Validation of the IBS-QOL: Female Mexican IBS Patients Have Poorer Quality of Life Than Females from North Carolina. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2950-2955.	2.3	27
69	Prevalence of Functional GI Disorders in Women with History of Domestic Violence. Does the Type of Abuse Matter?. <i>American Journal of Gastroenterology</i> , 2007, 102, S511.	0.4	0
70	A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. <i>Journal of Psychosomatic Research</i> , 2006, 61, 461-467.	2.6	29
71	Frequency of Functional Bowel Disorders among Healthy Volunteers in Mexico City. <i>Digestive Diseases</i> , 2006, 24, 342-347.	1.9	63
72	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R277-R284.	1.8	97

#	ARTICLE	IF	CITATIONS
73	Intestinal involvement is not sufficient to explain hypertransaminasemia in celiac disease?. Medical Hypotheses, 2005, 65, 937-941.	1.5	21
74	Maximum tolerated volume in drinking tests with water and a nutritional beverage for the diagnosis of functional dyspepsia. World Journal of Gastroenterology, 2005, 11, 3122.	3.3	18
75	CASE REPORT: Endoscopic Balloon Catheter Dilation for Treatment of Primary Cricopharyngeal Dysfunction. Digestive Diseases and Sciences, 2004, 49, 1612-1614.	2.3	10
76	Current and future treatment of chest pain of presumed esophageal origin. Gastroenterology Clinics of North America, 2004, 33, 93-105.	2.2	14
77	DRINKING TEST WITH WATER OR NUTRITIONAL BEVERAGE DISCRIMINATES BETWEEN NORMAL SUBJECTS AND PATIENTS WITH FUNCTIONAL DYSPEPSIA. American Journal of Gastroenterology, 2004, 99, S280-S281.	0.4	0
78	Clinical characteristics and QOL in IBS patients from Mexico and the USA: Are they different?. Gastroenterology, 2003, 124, A395.	1.3	2
79	Frequency of different subgroups of patients with non erosive gastroesophageal reflux disease (NERD) according to esophageal acid exposure and symptom index. Gastroenterology, 2003, 124, A538.	1.3	2
80	The role of gender and bowel habit predominance on visceral perception in IBS. Gastroenterology, 2001, 120, A755.	1.3	3
81	Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. American Journal of Gastroenterology, 2001, 96, 3341-3347.	0.4	163
82	Chest pain of esophageal origin. Current Opinion in Gastroenterology, 2001, 17, 376-380.	2.3	29
83	Irritable Bowel Syndrome in Mexico. Digestive Diseases, 2001, 19, 251-257.	1.9	12
84	Gender-related differences in IBS symptoms. American Journal of Gastroenterology, 2001, 96, 2184-2193.	0.4	190
85	Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. American Journal of Gastroenterology, 2000, 95, 152-156.	0.4	71
86	Symptom Differences in Moderate to Severe IBS Patients Based on Predominant Bowel Habit. American Journal of Gastroenterology, 1999, 94, 2929-2935.	0.4	109
87	Symptoms and Visceral Perception in Patients With Pain-Predominant Irritable Bowel Syndrome. American Journal of Gastroenterology, 1999, 94, 1320-1326.	0.4	171
88	Common functional gastrointestinal disorders: Nonulcer dyspepsia and irritable bowel syndrome. Clinical Cornerstone, 1999, 1, 57-71.	0.7	9
89	Evolving concepts in irritable bowel syndrome. Current Opinion in Gastroenterology, 1999, 15, 16.	2.3	10
90	9 Gastrointestinal sensory abnormalities in functional dyspepsia. Bailliere's Clinical Gastroenterology, 1998, 12, 545-556.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Helicobacter pylori Infection Among Patients with Alcoholic and Nonalcoholic Cirrhosis. Helicobacter, 1997, 2, 149-151.	3.5	16